Monopar Therapeutics Sets August 5th Annual Meeting

TL;DR

Monopar's annual meeting is Aug 5th. Proxy filing is in. No fee.

AI Summary

Monopar Therapeutics Inc. filed a definitive proxy statement (DEF 14A) for its annual meeting of stockholders scheduled for August 5, 2024. The filing indicates no fee was required for this submission. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and proposals for the annual meeting, influencing corporate governance and future strategic decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating any immediate financial or operational distress.

Key Numbers

• August 5, 2024 — Annual Meeting Date (Date for stockholders to vote on corporate matters.)

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• August 5, 2024 (date) — Annual Meeting Date
• 20240722 (date) — Filing Date

FAQ

Filing Documents

• mnpr20240714_def14a.htm (DEF 14A) — 828KB
• m01.jpg (GRAPHIC) — 5KB
• sig01.jpg (GRAPHIC) — 2KB
• 0001437749-24-023123.txt ( ) — 839KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 25 Summary Compensation Table 25 Outstanding Equity Awards at December 31, 2023 26 Potential Payments upon Termination or Change in Control 27 Pension Benefits 27 401(k) Plan 27 Nonqualified Deferred Compensation 27 Hedging Policy 27 CERTAIN RELATIONSHIPS AND RELATED-PERSON TRANSACTIONS 28 Relationships and Related-Person Transactions 28 Registration Rights 28 Procedures for Related-Person Transactions 28

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 28 OTHER BUSINESS 30 SECURITY HOLDER COMMUNICATIONS TO THE BOARD OF DIRECTORS 30 STOCKHOLDER PROPOSALS 30 DELIVERY OF PROXY STATEMENT 30 ANNEX A : CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 31 ANNEX B: MONOPAR THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN 32 Table of Contents MONOPAR THERAPEUTICS INC. 1000 Skokie Blvd., Suite 350 Wilmette, IL 60091 PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on August 5, 2024 at 10:00am Central Time at Monopar Therapeutics Inc. 1000 Skokie Blvd. Wilmette, IL 60091 GENERAL INFORMATION This Proxy Statement is furnished in connection with Monopar Therapeutics Inc.'s ("Monopar" or the "Company") 2024 Annual Meeting of Stockholders, to be held on August 5, 2024, at 10:00am Central Time (the "Annual Meeting") at the Company's headquarters located at 1000 Skokie Blvd., Wilmette, IL 60091. This Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2023 (the "Annual Report") is first being mailed on or about July 22, 2024. The Proxy Statement and Annual Report on Form 10-K are available at www.monopartx.com in the "Annual Meeting" subsection of the "Investors" tab. We will pay all of the costs of distributing this Proxy Statement. . Shares Outstanding and Voting Rights Only holders of record of our common stock at the close of business on July 12, 2024 (the "Record Date"), are entitled to notice of and to vote at the Annual Meeting. On July 12, 2024, 17,601,827 shares of common stock were issued and outstanding. Each share of common stock is entitled to one vote on all matters to be voted upon at the Annual Meeting. Holders of common stock do not have the right to cumulative voting in the election of directors. Quorum and Vote of Monopar Stockholders Required A quorum of stockholders is necessary to hold a valid meeting. The pre

View Full Filing

View this DEF 14A filing on SEC EDGAR